Fosbretabulin
- Generic Name
- Fosbretabulin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H21O8P
- CAS Number
- 222030-63-9
- Unique Ingredient Identifier
- I5590ES2QZ
- Background
Fosbretabulin has been investigated for the treatment of Anaplastic Thyroid Cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression
- Conditions
- Interventions
- First Posted Date
- 2017-01-09
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- Lowell Anthony, MD
- Target Recruit Count
- 17
- Registration Number
- NCT03014297
- Locations
- πΊπΈ
University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States
Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- Mateon Therapeutics
- Target Recruit Count
- 7
- Registration Number
- NCT02279602
- Locations
- πΊπΈ
Froedtert Hospital, Medicial College of Wisconsin, Milwaukee, Wisconsin, United States
πΊπΈMontefiore, Bronx, New York, United States
πΊπΈMarkey Cancer Center, Clinical Research Office, Lexington, Kentucky, United States
PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-02-05
- Last Posted Date
- 2021-05-17
- Lead Sponsor
- The Christie NHS Foundation Trust
- Target Recruit Count
- 21
- Registration Number
- NCT02055690
- Locations
- π¬π§
University Collage London Hospitals NHS Foundation Trust, London, United Kingdom
π¬π§The Christie NHS Foundation Trust, Manchester, United Kingdom
π¬π§Freeman Hospital (Newcastle-upon-Tyne Hospitals NHS Foundation Trust), Newcastle Upon Tyne, United Kingdom
Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2012-04-04
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 8
- Registration Number
- NCT01570790
- Locations
- πΊπΈ
Wilmer Eye Institute, Baltimore, Maryland, United States
Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
- Conditions
- Interventions
- First Posted Date
- 2011-08-25
- Last Posted Date
- 2011-11-01
- Lead Sponsor
- Mateon Therapeutics
- Target Recruit Count
- 23
- Registration Number
- NCT01423149
Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV)
- Conditions
- Interventions
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2011-11-01
- Lead Sponsor
- Mateon Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT01023295
- Locations
- π¨π³
OXiGENE Investigational Site, Changhua, Taiwan
A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2015-02-09
- Lead Sponsor
- Mateon Therapeutics
- Target Recruit Count
- 63
- Registration Number
- NCT00653939
- Locations
- πΊπΈ
Pacific Coast Hematology and Oncology Medical Group, Fountain Valley, California, United States
πΊπΈThe Mark H. Zangmeister Center, Columbus, Ohio, United States
πΊπΈSouthbay Oncology Hematology, Campbell, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.